BANGKOK– Economic ties between Thailand and the United States have reached a historic high, with trade volume soaring past US$110 billionin 2025. However, this growing partnership is facing a significant test. Despite the record-breaking numbers, the Office of the United States Trade Representative (USTR) has released a detailed report urging Bangkok to remove long-standing “non-tariff barriers” that hinder American businesses.
Washington is specifically pressing Thailand to streamline regulations in three critical sectors: automotive standards, pharmaceutical approvals, and agricultural imports. These discussions are part of a broader push to finalize a reciprocal trade deal that could redefine commerce in Southeast Asia.
The Roadblocks in the Thai Auto Market
One of the most persistent issues involves how cars are certified for sale. Currently, vehicles manufactured in the U.S. follow the Federal Motor Vehicle Safety Standards (FMVSS). However, Thailand largely adheres to regulations based on the United Nations Economic Commission for Europe (UNECE).
Because of this discrepancy, American-made cars cannot be sold directly in Thailand without undergoing expensive and time-consuming re-testing.
- Cost and Complexity:American exporters face heavy administrative burdens to meet Thai-specific requirements.
- Market Demand:U.S. manufacturers excel in producing large pickup trucks and SUVs—categories that are incredibly popular with Thai consumers.
- Future Tech:Easier access would likely accelerate the availability of U.S. electric vehicles (EVs) and advanced automotive technology in the region.
The USTR argues that recognizing U.S. safety standards would be a win-win, offering Thai consumers more choices while lowering costs for manufacturers.
Faster Access to Life-Saving Medicines
The healthcare sector is another major point of contention. Under a joint framework established in October 2025, Thailand reportedly committed to accepting U.S. Food and Drug Administration (FDA)certifications as sufficient for local market entry.
However, the USTR notes that American pharmaceutical companies still face a “duplicative” approval process. This means that even if a drug or medical device is proven safe and effective by the world-renowned U.S. FDA, it must often jump through the same hoops again in Thailand.
Why this matters for Thai citizens:
- Innovation Delays:Red tape can delay the arrival of new treatments for cancer, rare diseases, and chronic conditions.
- Higher Costs:The extra time and money spent on local certification often trickle down to the patient.
- Regional Competitiveness:Countries that recognize international standards often receive the latest medical innovations months or even years before those that do not.
The Long-Standing Battle Over Agriculture
While cars and medicine represent the future, a decades-old dispute over pork and farm goods continues to simmer. The U.S. has long complained about Thailand’s restrictions on American agricultural products, particularly pork.
In late 2020, Washington went as far as suspending approximately one-sixth of Thailand’s Generalized System of Preferences (GSP) benefits—a program that allows certain products to enter the U.S. duty-free—because of these market access issues.
The USTR’s latest report highlights that the Department of Livestock Development (DLD)in Thailand has yet to publish clear import procedures for individual U.S. suppliers. This has left many American farmers in “limbo,” unable to plan or ship goods despite high demand.
The tension comes at a delicate time. Both nations are working toward a reciprocal trade agreement intended to liberalize trade further. This agreement is expected to build upon the commitments made in the October 2025 joint statement.
For Thailand, easing these barriers could mean more American investment and a faster transition to a high-tech economy. For the U.S., it opens the door to one of the most vibrant consumer markets in the ASEAN region .
As negotiations continue, all eyes are on Bangkok to see if it will follow through on its pledges to modernize its trade standards. If successful, the $110 billion trade figure seen in 2025 might just be the beginning of a much larger economic story.
